For example, CRP is less likely to be elevated under anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis since the release of CRP is affected by IL-6; therefore, it is not useful for assessing disease activity [23]. This evidence concerns the gene IL6 and rheumatoid arthritis.